07:50 AM EDT, 05/22/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Thursday reported what it called "encouraging" early Phase 1b data involving five adult male patients with Duchenne muscular dystrophy (DMD) who were treated with its lead compound SAT-3247 over 28 days.

The results show that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD, the company said in a statement. The treatment was also safe and well-tolerated.

Satellos plans to begin an 11-month follow-up study, which has already received ethics committee approval in Australia. First-patient dosing is expected in the third quarter of this year, pending qualification of the clinical site. The study will include MRI imaging to assess possible changes in muscle and will measure grip strength every three months, and additional functional and biomarker measurements.